Comparative Pharmacology
Head-to-head clinical analysis: BRIMONIDINE TARTRATE TIMOLOL MALEATE versus LOPRESSOR HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIMONIDINE TARTRATE TIMOLOL MALEATE versus LOPRESSOR HCT.
BRIMONIDINE TARTRATE; TIMOLOL MALEATE vs LOPRESSOR HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brimonidine is a selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow. Timolol is a non-selective beta-adrenergic receptor blocker that decreases aqueous humor production by inhibiting beta-2 receptors in the ciliary epithelium.
LOPRESSOR HCT is a combination of metoprolol tartrate (a beta-1 selective adrenergic receptor blocker) and hydrochlorothiazide (a thiazide diuretic). Metoprolol reduces heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing plasma volume.
One drop of the fixed combination (0.2% brimonidine/0.5% timolol) in the affected eye(s) twice daily, approximately 12 hours apart.
1-2 tablets (each containing metoprolol tartrate 50 mg and hydrochlorothiazide 25 mg) orally once daily, maximum 4 tablets daily.
None Documented
None Documented
Brimonidine: ~3 hours (terminal); timolol: ~4–6 hours (terminal). Clinical context: allows twice-daily dosing for brimonidine/timolol combination.
Metoprolol: 3-7 hours (terminal half-life); extensive metabolizers (CYP2D6) ~3-4 h, poor metabolizers ~7-8 h. Hydrochlorothiazide: 6-15 hours (terminal half-life).
Brimonidine: primarily renal (74% as unchanged drug); timolol: renal (20% unchanged, remainder as metabolites) and fecal (small amount).
Metoprolol: <5% unchanged in urine; rest metabolized in liver (CYP2D6) and excreted renally as metabolites. Hydrochlorothiazide: >95% excreted unchanged in urine within 24 hours via tubular secretion.
Category A/B
Category C
Beta-Blocker
Beta-Blocker/Thiazide Diuretic Combination